This is significant because a wide range of MEK mutations are frequently found in vemurafenib/dabrafenib-resistant melanomas and in primary untreated melanomas.3 That MEK has shown susceptibility to a particularly broad spectrum of gain-of-function mutations highlights the many escape routes to activation and its evolutionary flexibility in the context of melanoma pathogenesis. This evidence concerns the gene MAP2K7 and melanoma.